ReNetX Bio Announces Key Scientific Publication Validating Preclinical Translation with Lead Molecule

New Haven, Conn., July 13, 2020 -- ReNetX Bio, Inc., a clinical stage biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal damage, announces the publication of a key article in *Brain* validating the company's novel approach to addressing damage in the central and ocular nervous system and the *potential to reverse damage from neurological disorders.*

The lead compound, AXER-204, is currently in Phase 1/2 clinical trials and this new data provides significant preclinical translational evidence of efficacy in reversing axonal loss. The publication, a research effort led by Dr. Stephen Strittmatter of Yale University, has confirmed greater corticospinal tract growth and behavioral recovery following treatment with AXER-204. This confirmation of axon growth and recovery extends similar findings in numerous earlier preclinical studies and has far-reaching implications for drug development in neurological injury and neurodegenerative diseases. "The company's novel approach to blocking the action of myelin associated inhibitors at the NgR1 receptor, a well-established axon growth inhibitory pathway, is a potentially transformative drug target with broad therapeutic applications for patients, and Dr. Strittmatter's research provides critical validation supporting the potential for clinical translation," said Erika R. Smith, CEO of ReNetX Bio. "This work provides further evidence to support ReNetX Bio's clinical program and efforts to develop drugs for neurological diseases with substantial unmet medical need."

In the scientific commentary concurrently published in *Brain*, the authors emphasize the impact of these results as well as their significance addressing the unmet need for patients. Dr. George Maynard, President and CSO of ReNetX Bio, further comments that "we look to our continued partnership with Dr. Strittmatter and share his vision for developing targeted treatments for severe neurological disorders."

About the Phase 1/2 RESET Study: For more information, see ClinicalTrials.gov
About ReNetX Bio, Inc.: For more information, please visit www.renetx.com